The ODT tablet should be placed on the tongue where it will disintegrate rapidly and can be swallowed with or without water. Do not chew or crush the tablet. Take approximately 1 hour before chemotherapy or anesthesia.

Palonosetron is a highly selective 5-HT3 receptor antagonist. Serotonin 5-HT3 receptors are located both peripherally on vagal nerve terminals in the gastrointestinal tract and centrally in the chemoreceptor trigger zone. Chemotherapeutic agents and radiation therapy are thought to cause the release of serotonin from enterochromaffin cells of the small intestine, which then activates vagal afferents via 5-HT3 receptors, initiating the vomiting reflex. Palonosetron blocks this action, thereby preventing nausea and vomiting.

• •Hypersensitivity to palonosetron or any component of the formulation.
• •Known hypersensitivity to other 5-HT3 receptor antagonists.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

There is no specific antidote for palonosetron overdose. Treatment should be symptomatic and supportive. Patients should be monitored for signs of serotonin syndrome and QT prolongation.

Pregnancy Category B. Use only if clearly needed. It is not known whether palonosetron is excreted in human milk; caution should be exercised when administered to a nursing woman.